Nonclinical Efficacy Testing » Essential Information Before Requesting a Nonclinical Study » cross-compare scientific evaluation designs

cross-compare scientific evaluation designs

In the design of non-clinical study evaluations, it is necessary to first define "what you want to clarify" and then combine the modality, target and mechanism of action, disease stage, model, and evaluation endpoints to suit that question.

Here, rather than simply comparing CRO company information, we comprehensively organize everything from scientific validation challenges to exposure, target binding and confirmation, pharmacodynamics, efficacy, translational biomarkers, and safety.

How to proceed with scientific evaluation design

1Verification task

2Modality

3Target and mechanism of action

4stage

5Model

6Evaluation items

7client contractor

How to read the comparison table

The pale yellow columns are the core items of the evaluation design. For the verification challenges, evaluations ranging from exposure to safety will be considered as a single package.

Compare evaluation designs by disease and modality

Even within the same disease area, required endpoints and considerations vary depending on the disease stage, modality, target, and models used. The table below organizes representative combinations and items to check.

You can view the table by scrolling up, down, left, and right.

Disease/Area	Stage and evaluation phase	Modality	target	Mechanism of Action (MoA)	Model	animal species	scientific verification challenge	exposure	Target binding and effect confirmation	pharmacodynamics (PD)	medicinal effect	translational biomarker	Safety	evaluation technology	positive control / benchmark	Scientific notes	Required evidence
tumor immunity	Established tumor	Antibody drug	PD-1	PD-1/PD-L1 blockade	Syngeneic tumor	Mouse	Will immune checkpoint inhibition produce an antitumor effect?	Serum PK	PD-1 receptor occupancy / binding blockade	CD8 activation, Ki-67, IFN-γ, Granzyme B	Tumor volume, TGI, regression, survival	Peripheral/tumor immune phenotype	clinical pathology, histopathology, cytokine-related findings	Flow cytometry, IHC, bioanalysis, tumor measurement	anti-PD-1 (set according to model sensitivity)	Confirm the mouse cross-reactivity and tumor cell line sensitivity of the target antibody	Literature + Provider validation data
tumor immunity	Established tumor	Antibody drug	PD-1	PD-1/PD-L1 blockade	Humanized mouse	Mouse	Can the pharmacology of human-specific anti-PD-1 antibodies be evaluated?	Serum PK	Human PD-1 occupancy/binding	Human T-cell activation, cytokines	Tumor burden, survival	Human immune-cell phenotype	GVHD、cytokine-related findings、tissue pathology	Flow cytometry、IHC、bioanalysis	製品・モデルごとに設定	Donor variability、human immune reconstitution、GVHDを考慮	Provider validation data＋文献
MASH	MASH～線維化	低分子／抗体／核酸等	各薬剤標的	標的依存	STAM™	Mouse	代謝異常を背景に炎症・線維化を改善するか	PK／tissue exposure	標的依存	標的下流biomarker	Histology、fibrosis、liver injury、metabolic phenotype	ALT／AST、lipid、circulating biomarker	Clinical chemistry、histopathology	Histology、IHC、qPCR、biochemistry	目的・病期・MoAに応じ設定	HCCまで見るか、MASH・線維化で止めるかによって評価時点が変わる	Model validation＋文献
MASH	線維化進展	低分子／抗体／核酸等	各薬剤標的	抗線維化／代謝改善等	WD＋CCl4	Mouse	ongoing injury下で抗線維化作用があるか	PK／liver exposure	標的依存	Fibrogenic pathway marker	Fibrosis area、collagen、α-SMA、liver injury	ALT／AST、fibrosis biomarkers	Clinical chemistry、pathology	Sirius Red／Masson、IHC、qPCR、biochemistry	目的に応じ設定	食餌、CCl4 dose、開始時の線維化stageを揃える必要がある	Provider protocol＋validation data
MASH	線維化優位	低分子／抗体等	各薬剤標的	抗線維化	CCl4 fibrosis	Mouse／Rat	代謝要因を切り離して直接的な抗線維化作用を見る	PK／tissue exposure	標的依存	Fibrosis pathway marker	Collagen、α-SMA、fibrosis area、hydroxyproline	Fibrosis biomarker	Pathology、clinical chemistry	Histology、IHC、qPCR、biochemical assay	目的に応じ設定	代謝性MASHを再現するモデルではない	文献＋Provider protocol
IPF	Inflammatory-to-fibrotic phase	低分子／抗体／核酸等	各薬剤標的	抗線維化／抗炎症等	Bleomycin	Mouse／Rat	肺線維化を抑え、必要に応じて肺機能も改善するか	PK／lung exposure	標的依存	Target-pathway marker	Ashcroft、collagen／Hyp、lung function	BALF、circulating／tissue fibrosis marker	Body weight、clinical observation、pathology	Histology、IHC、BALF、qPCR、lung function	nintedanib／pirfenidone等を目的別に検討	予防・治療デザイン、自然退縮、誘導法、肺葉差に注意	Literature + Provider validation data
CKD／腎線維化	Post-injury fibrosis	低分子／抗体／核酸等	各薬剤標的	抗線維化／抗炎症	UUO	Mouse／Rat	腎線維化経路への直接作用があるか	PK／kidney exposure	標的依存	Fibrosis／inflammation pathway marker	Fibrosis area、α-SMA、collagen	Kim-1等の腎障害marker	Histopathology、body weight／clinical observation	Histology、IHC、qPCR	目的に応じ設定	閉塞腎のため、腎機能readoutの解釈に制限がある	文献＋Provider protocol
CKD／DKD	Diabetic kidney disease	低分子／抗体／核酸等	各薬剤標的	代謝改善／腎保護等	db/db	Mouse	糖尿病を背景とする腎障害を改善するか	PK	標的依存	Target-pathway marker	uACR、renal pathology、renal function-related endpoints	Urinary／serum renal biomarkers	Clinical chemistry、pathology	Urine chemistry、histology、IHC、qPCR	目的に応じ設定	病期、週齢、系統条件によって腎表現型が変わる	Literature + Provider validation data
Nucleic acid medicine	Target knockdown	ASO／siRNA	RNA target	Knockdown／splice modulation	Disease-specific model	Species dependent	標的組織で十分にノックダウンできるか	Plasma／tissue exposure	Target RNA reduction／engagement	mRNA／protein knockdown	Disease-specific efficacy endpoint	Circulating／tissue target biomarker	Liver／kidney and sequence／class-related safety as appropriate	qPCR／ddPCR、protein assay、bioanalysis、pathology	Sequence／target-specific benchmark	Species homology、delivery、標的組織分布が重要	規制ガイドライン＋文献
mRNA	Protein expression	mRNA／LNP	Encoded target	Protein expression	Disease-specific model	Species dependent	目的組織へ送達され、機能タンパク質が発現するか	mRNA／LNP or expressed-protein exposure	Delivery／expression	Encoded protein／downstream biomarker	Disease-specific endpoint	Expression biomarker	Innate immune、local／systemic toxicity	qPCR／ddPCR、protein assay、bioanalysis、biodistribution	Platform／target-specific benchmark	LNP分布、発現持続、自然免疫活性化を分けて評価	規制ガイドライン＋文献
ADC	Target-positive tumor	ADC	Tumor antigen	Targeted payload delivery	Xenograft／PDX／other suitable tumor model	Mouse	標的選択的にpayloadを届け、抗腫瘍効果を示すか	ADC／total Ab／payload PK	Binding／internalization	Payload PD／target modulation	TGI、regression、survival	Tumor target expression／circulating marker	On-target／off-tumor、payload-related toxicity	IHC、bioanalysis、tumor measurement、pathology	Reference ADC／payload comparator where appropriate	Target expression density、internalization、payload sensitivityが重要	Literature + Provider validation data
CAR-T／細胞治療	Target-positive tumor	細胞治療	Cell-surface antigen	Cell-mediated cytotoxicity	Humanized／xenograft／suitable model	Mouse	細胞が増殖・持続し、腫瘍へ移行して抗腫瘍効果を示すか	Cell kinetics／persistence	CAR+ cells／target interaction	Expansion、activation、cytokines	Tumor burden, survival	Peripheral／tumor immune-cell kinetics	CRS-like signals、off-target tissue injury	Flow cytometry、imaging、qPCR、cytokine assay、pathology	Product-specific benchmark	Trafficking、persistence、target expression、model immune contextが重要	規制ガイドライン＋文献

公開情報や検証情報がない項目は、「非対応」と判断せず、受託先への確認が必要な項目として扱います。

Regarding the published information

本表は、代表的な評価設計を比較しやすく整理したものです。実際に必要となる試験、評価項目、動物種、モデル、陽性対照、技術、根拠資料は、被験物質の特性や開発段階によって異なります。具体的な試験計画は、専門家や受託先と相談のうえ決定してください。

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us